247 related articles for article (PubMed ID: 33002502)
1. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells.
Song L; Bretz AC; Gravemeyer J; Spassova I; Muminova S; Gambichler T; Sriram A; Ferrone S; Becker JC
J Invest Dermatol; 2021 Apr; 141(4):903-912.e4. PubMed ID: 33002502
[TBL] [Abstract][Full Text] [Related]
2. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression.
Srinivas N; Song L; Lei KC; Gravemeyer J; Furtmann F; Gambichler T; Becker JC; Sriram A
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8267-8277. PubMed ID: 37071208
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.
Ritter C; Fan K; Paschen A; Reker Hardrup S; Ferrone S; Nghiem P; Ugurel S; Schrama D; Becker JC
Sci Rep; 2017 May; 7(1):2290. PubMed ID: 28536458
[TBL] [Abstract][Full Text] [Related]
5. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
6. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma.
Ritter C; Fan K; Paulson KG; Nghiem P; Schrama D; Becker JC
Sci Rep; 2016 Feb; 6():21678. PubMed ID: 26902929
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.
Paulson KG; Tegeder A; Willmes C; Iyer JG; Afanasiev OK; Schrama D; Koba S; Thibodeau R; Nagase K; Simonson WT; Seo A; Koelle DM; Madeleine M; Bhatia S; Nakajima H; Sano S; Hardwick JS; Disis ML; Cleary MA; Becker JC; Nghiem P
Cancer Immunol Res; 2014 Nov; 2(11):1071-9. PubMed ID: 25116754
[TBL] [Abstract][Full Text] [Related]
8. Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.
Ollier J; Kervarrec T; Samimi M; Benlalam H; Aumont P; Vivien R; Touzé A; Labarrière N; Vié H; Clémenceau B
Cancer Immunol Immunother; 2018 Aug; 67(8):1209-1219. PubMed ID: 29808366
[TBL] [Abstract][Full Text] [Related]
9. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.
Chapuis AG; Afanasiev OK; Iyer JG; Paulson KG; Parvathaneni U; Hwang JH; Lai I; Roberts IM; Sloan HL; Bhatia S; Shibuya KC; Gooley T; Desmarais C; Koelle DM; Yee C; Nghiem P
Cancer Immunol Res; 2014 Jan; 2(1):27-36. PubMed ID: 24432305
[TBL] [Abstract][Full Text] [Related]
10. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of Zeste Homolog 2 Inhibition Induces HLA Class I Re-Expression in Merkel Cell Carcinoma.
Durand MA; Drouin A; Bachiri K; Durand L; Berthon P; Houben R; Schrama D; Coyaud E; Samimi M; Touzé A; Kervarrec T
J Invest Dermatol; 2024 Jun; 144(6):1398-1401.e1. PubMed ID: 38052265
[No Abstract] [Full Text] [Related]
12. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
13. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
14. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
15. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
[TBL] [Abstract][Full Text] [Related]
16. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
Houben R; Hesbacher S; Sarma B; Schulte C; Sarosi EM; Popp S; Adam C; Kervarrec T; Schrama D
Cancer Lett; 2022 Jan; 524():259-267. PubMed ID: 34715251
[TBL] [Abstract][Full Text] [Related]
18. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
19. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
20. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
